Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 17;17(12):2021.
doi: 10.3390/cancers17122021.

Validation of the Updated Porto Proposal in Papillary Thyroid Microtumors: Analysis of Cases at a University Hospital in Catalonia, Spain

Affiliations

Validation of the Updated Porto Proposal in Papillary Thyroid Microtumors: Analysis of Cases at a University Hospital in Catalonia, Spain

Karmele Saez de Gordoa et al. Cancers (Basel). .

Abstract

Background/Objectives: Given the high incidence and generally favorable prognosis of papillary thyroid microcarcinomas (PTMs), the Porto Proposal aims to refine the management of these tumors. It designates tumors lacking certain risk factors as papillary microtumors (PMTs) to avoid overtreatment and reduce patient stress. The updated Porto Proposal (uPp) suggests criteria for reclassifying incidental PTMs as PMTs. This study seeks to validate these criteria using data from a university hospital in Catalonia, Spain, and assess the clinical and pathological characteristics of PTMs. Methods: This retrospective study analyzed patients diagnosed with PTM (≤1 cm) at a university hospital from 2000 to 2024. The study examined variables, including lymph node positivity, incidental diagnosis, tumor location, histological type, treatment, multifocality, age at diagnosis, tumor size, and survival. The uPp criteria were applied to reclassify PTMs into PMTs or PMCs (true papillary microcarcinomas). Student's t-test and chi-square tests were used to evaluate the associations between these variables and the uPp classification. Results: The cohort comprised 107 patients, with 77 (72%) women and 30 men. The mean age at diagnosis was 54.5 years. Out of the total, 77 (72%) cases were reclassified as PMTs and 30 (28%) as PMCs according to the uPp criteria. PMC tumors were larger (mean size 4.5 mm vs. 3.3 mm for PMT, p = 0.014) and were significantly associated with multifocality (52.2%; p = 0.004). Most lymph node-positive cases were classified as PMCs (69.2%; p < 0.001) and were multifocal and bilateral more commonly. However, no significant differences in outcomes between PMCs and PMTs were found (p = 0.188). Follicular histology was significantly more common in PMTs (87.0%, p < 0.001) and rarely had lymph node metastases (4.6%; p = 0.047). Conclusions: The updated Porto Proposal (uPp) effectively identifies PTMs with minimal malignant potential, distinguishing between PMT and PMC. The findings support the protocol's use in reducing unnecessary treatments and psychological stress for patients. The study highlights significant clinical and pathological differences between PTM subtypes, reinforcing the protocol's applicability in daily pathological practice.

Keywords: Porto proposal; histopathology; minimally invasive treatment; papillary microtumor; papillary thyroid microcarcinoma; risk stratification; thyroid cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart summarizing the selection process for the study cohort. From an initial database of 425 thyroid carcinoma cases diagnosed between 2000 and 2024, exclusions were applied for tumor size > 1 cm, prior thyroid carcinoma history, incomplete clinical or pathological data, and non-incidental diagnosis. The final study cohort comprised 107 patients with papillary thyroid microcarcinomas (PTMs ≤ 1 cm), subsequently classified according to the updated Porto Proposal criteria into papillary microtumors (PMTs) and papillary microcarcinomas (PMCs).
Figure 2
Figure 2
Features associated with papillary microcarcinomas. (a) Macroscopic image of a multifocal tumor (black line: 1 cm); (b) Multifocal tumor, with two foci of PTMs delineated in blue (1× magnification, black line 5 mm); (c) Tall cell subtype of PTMs measuring 6 mm, classified as a PMC (1× magnification, black line 5 mm); (d) High-power view of the tall cell tumor, showing a trabecular pattern, with cell height at least 2 times the cell width and distinct cell borders (40× magnification, black line 0.1 mm).
Figure 3
Figure 3
(a,b) Cervical lymph node with a lymph node metastasis of papillary thyroid carcinoma (5× and 20× magnification, black line: 1 mm and 0.2 mm, respectively); (c) Classic subtype of PTM, showing true papillae lined by cells with irregular and clear nuclei (20× magnification, black line 0.2 mm); (d) PTM with a follicular growth pattern, which is associated with a low risk of LNMs (20× magnification, black line 0.2 mm).

Similar articles

References

    1. Baloch Z.W., Asa S.L., Barletta J.A., Ghossein R.A., Juhlin C.C., Jung C.K., LiVolsi V.A., Papotti M.G., Sobrinho-Simões M., Tallini G., et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr. Pathol. 2022;33:27–63. doi: 10.1007/s12022-022-09707-3. - DOI - PubMed
    1. La Vecchia C., Malvezzi M., Bosetti C., Garavello W., Bertuccio P., Levi F., Negri E. Thyroid Cancer Mortality and Incidence: A Global Overview. Int. J. Cancer. 2015;136:2187–2195. doi: 10.1002/ijc.29251. - DOI - PubMed
    1. Kyrilli A., Schoinochoriti R., Chatzopoulos V., Bahar N., Bouziotis J., D’Haene N., Salmon I., Ruiz M., Corvilain B. Thyrotropin (TSH) and Thyroid Autoimmunity Are Predictive Factors for the Incidental Discovery of Papillary Thyroid Microcarcinoma during Thyroidectomy. Endocrine. 2024;86:723–731. doi: 10.1007/s12020-024-03907-z. - DOI - PubMed
    1. Zheng W., Wang X., Rui Z., Wang Y., Meng Z., Wang R. Clinical Features and Therapeutic Outcomes of Patients with Papillary Thyroid Microcarcinomas and Larger Tumors. Nucl. Med. Commun. 2019;40:477–483. doi: 10.1097/MNM.0000000000000991. - DOI - PubMed
    1. Sugitani I. Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 2023;37:101630. doi: 10.1016/j.beem.2022.101630. - DOI - PubMed

LinkOut - more resources